In this article, we are going to take a look at where Inari Medical, Inc. (NASDAQ:NARI) stands against other firms post strong gains amid Wall Street bloodbath. Wall Street’s main indices closed ...

Canaccord downgraded Inari Medical (NARI) to Hold from Buy with a price target of $80, up from $74, after Stryker (SYK) entered into a definitive agreement to acquire Inari in cash for $80 per share.

Inari Medical, Inc. NARI is well-poised for ... The company is currently engaged in the limited market release of Venacore, the second purpose-built tool within the CBD toolkit, expanding NARI ...

Inari Medical, Inc. NARI is well-poised for growth on the back of a huge market opportunity for its products and its commitment to understanding the venous system. However, the company’s dependency on ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Inari Medical, Inc. (NASDAQ:NARI – Get Free Report)’s share price traded down 4.6% during mid-day trading on Monday after an insider sold shares in the company.The stock traded as low as $52. ...

Analysts' ratings for Inari Medical NARI over the last quarter vary from bullish to bearish, as provided by 6 analysts. The following table encapsulates their recent ratings, offering a glimpse ...